<DOC>
	<DOC>NCT00757588</DOC>
	<brief_summary>The purpose of this study is to compare the effects of saxagliptin with those of placebo as add-on therapy to insulin and insulin with metformin in improving glycemic control at 24 and 52 weeks.</brief_summary>
	<brief_title>Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus Must have been taking a stable dose of basal or premixed insulin for 8 weeks or longer prior to screening If taking metformin, must have been taking the same daily dose for 8 weeks or longer prior to screening Insulin type should be intermediate or longacting (basal) or premixed (premixed formulation may include short or rapidacting insulin as 1 component). Inadequate glycemic control (A1C of 7.5% to 11.0%, inclusive) Body mass index of 45 kg/mÂ² or lower Fasting Cpeptide level of 0.8 ng/mL or higher Symptoms of poorly controlled diabetes, including but not limited to marked polyuria and polydipsia with greater than 10% weight loss during the last 3 months prior to screening or other signs and symptoms History of diabetic ketoacidosis or hyperosmolar nonketotic coma Women of childbearing potential unable or unwilling to use acceptable birth control Women who are pregnant or breastfeeding Active liver disease Anemia Chronic or repeated intermittent corticosteroid treatment (participants receiving stable doses of replacement corticosteroid (except dexamethasone) therapy may be enrolled) Use of short or rapidacting insulin Significant cardiovascular history defined as: myocardial infarction, coronary angioplasty or bypass graft, valvular disease or repair, unstable angina pectoris, transient ischemic attack, or cerebrovascular accident Congestive heart failure Unstable or rapidly progressing renal disease History of alcohol or drug abuse within the previous year History of hemoglobinopathies Unstable major psychiatric disorders Immunocompromised status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>